Colorectal cancer is the third-most-common cancer globally and is associated with a five-year OS of Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in combination with angiogenesis inhibitors and EGFR inhibitors. Several areas of high unmet need—notably, treatments for the adjuvant and first-line patient populations—offer significant commercial opportunity for innovative agents. Several immune checkpoint inhibitors are in early- and late-phase development across lines of therapy and have the potential to significantly alter the treatment paradigm. This report provides insight on how treatment options for colorectal cancer are likely to change over the 2015-2025 forecast period. It also analyzes the current and future earnings potential of drugs already in the market and those expected to be approved for colorectal cancer.
- We forecast that the colorectal cancer therapy market will grow modestly over the 2015-2025 study period. What are the key drivers of this market’s growth? What will be the major constraints on its growth? What are the drug development activities of note? What challenges and opportunities remain?
- Two immune checkpoint inhibitors—Tecentriq (Genentech’s atezolizumab) and Keytruda (Merck & ;s pembrolizumab)—have entered Phase III clinical development for the treatment colorectal cancer. What is thought-leader opinion of these agents and of this drug class? In which patient populations will these agents be positioned? How will their use change over the next ten years? How will use of these agents affect prescribing of other agents for colorectal cancer?
- In 2014, Lonsurf (Taiho Pharmaceutical’s tipiracil/trifluridine) was approved for third- and later-line treatment of colorectal cancer. How do key opinion leaders perceive this agent? What impact will Lonsurf have on the market during the 2015-2025 forecast period? Where will Lonsurf experience the strongest uptake?
- The second-to-market tyrosine kinase inhibitor Vargatef (Boehringer Ingelheim’s nintedanib) and the first triple combination—binimetinib plus encorafenib (Array BioPharma) and Erbitux—are in Phase III clinical development for metastatic colorectal cancer. What do experts think of these agents? If these agents are approved, in which patient populations will they be positioned? How will their use change over the forecast period, and how will it affect the dynamics of each patient population?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 21 country-specific interviews with thought leaders.
Epidemiology: diagnosed incident cases of stage I, II, III , and IV colorectal cancer.
Population segments in market forecast :
Colon cancer stage II, rectal cancer stage II, colon cancer stage III, rectal cancer stage III, stage IV colorectal cancer wild-type RAS, first-line, stage IV colorectal cancer mutant RAS, first-line, stage IV colorectal cancer wild-type RAS, second-line, stage IV colorectal cancer mutant RAS , second-line, stage IV colorectal cancer wild-type RAS, third-line, stage IV colorectal cancer mutant RAS, third-line, stage IV colorectal cancer wild-type RAS, fourth-line, stage IV colorectal cancer mutant RAS, fourth-line.
Emerging therapies: Phase III: 15 drugs; Phase II: 20 drugs; Phase I: 14 drugs.